BrainsWay Ltd. (BWAY)

Market Cap	222.86M
Revenue (ttm)	43.46M
Net Income (ttm)	3.92M
Shares Out	36.90M
EPS (ttm)	0.08
PE Ratio	56.90
Forward PE	40.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,876
Open	11.49
Previous Close	11.68
Day's Range	11.42 - 11.49
52-Week Range	5.98 - 13.66
Beta	0.32
Analysts	Strong Buy
Price Target	14.25 (+24.78%)
Earnings Date	Aug 13, 2025

About ACCD

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 17, 2019
• Employees: 120
• Stock Exchange: NASDAQ
• Ticker Symbol: BWAY
• Website: https://www.brainsway.com

Analyst Summary

According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 24.78% from the latest price.

Price Target

$14.25

(24.78% upside)

Analyst Consensus: Strong Buy